Blockchain Registration Transaction Record

LIXTE Biotech Acquires Liora, Advancing Proton Therapy with LiGHT System

LIXTE Biotech acquires Liora Technologies, gaining the LiGHT system for advanced proton therapy. This strategic move expands cancer treatment options with innovative radiotherapy technology.

This acquisition matters because it accelerates the integration of advanced proton therapy into mainstream cancer care, potentially offering more precise and less invasive treatment options. Proton therapy, with its ability to target tumors while sparing healthy tissue, represents a significant advancement over traditional radiation, reducing side effects and improving patient quality of life. By combining Liora's LiGHT system with LIXTE's drug development expertise, this move could lead to more effective, personalized cancer treatments, addressing a global health challenge that impacts millions. It signals a shift toward holistic approaches in oncology, where radiotherapy and pharmaceuticals work synergistically, potentially speeding up innovations that save lives and reduce healthcare burdens.